ATE525391T1 - Muteine des c5a anaphylatoxins, für solche muteine kodierende nukleinsäuremoleküle, sowie pharmazeutische verwendungen von muteinen des c5a anaphylatoxins - Google Patents

Muteine des c5a anaphylatoxins, für solche muteine kodierende nukleinsäuremoleküle, sowie pharmazeutische verwendungen von muteinen des c5a anaphylatoxins

Info

Publication number
ATE525391T1
ATE525391T1 AT02807051T AT02807051T ATE525391T1 AT E525391 T1 ATE525391 T1 AT E525391T1 AT 02807051 T AT02807051 T AT 02807051T AT 02807051 T AT02807051 T AT 02807051T AT E525391 T1 ATE525391 T1 AT E525391T1
Authority
AT
Austria
Prior art keywords
muteins
anaphylatoxin
nucleic acid
acid molecules
pharmaceutical uses
Prior art date
Application number
AT02807051T
Other languages
English (en)
Inventor
Magnus Otto
Joerg Koehl
Original Assignee
Cincinnati Childrens S Hospital Medical Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cincinnati Childrens S Hospital Medical Ct filed Critical Cincinnati Childrens S Hospital Medical Ct
Application granted granted Critical
Publication of ATE525391T1 publication Critical patent/ATE525391T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02807051T 2002-03-19 2002-03-19 Muteine des c5a anaphylatoxins, für solche muteine kodierende nukleinsäuremoleküle, sowie pharmazeutische verwendungen von muteinen des c5a anaphylatoxins ATE525391T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2002/003035 WO2003078457A1 (en) 2002-03-19 2002-03-19 MUTEINS OF THE C5a ANAPHYLATOXIN, NUCLEIC ACID MOLECULES ENCODING SUCH MUTEINS, AND PHARMACEUTICAL USES OF MUTEINS OF THE C5a ANAPHYLATOXIN

Publications (1)

Publication Number Publication Date
ATE525391T1 true ATE525391T1 (de) 2011-10-15

Family

ID=27838004

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02807051T ATE525391T1 (de) 2002-03-19 2002-03-19 Muteine des c5a anaphylatoxins, für solche muteine kodierende nukleinsäuremoleküle, sowie pharmazeutische verwendungen von muteinen des c5a anaphylatoxins

Country Status (5)

Country Link
US (1) US8524862B2 (de)
EP (1) EP1492811B1 (de)
JP (1) JP4290564B2 (de)
AT (1) ATE525391T1 (de)
WO (1) WO2003078457A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
US20070141548A1 (en) 2005-03-11 2007-06-21 Jorg Kohl Organ transplant solutions and method for transplanting organs
EP2129681A2 (de) * 2007-03-22 2009-12-09 Novartis Ag C5-antigene und deren verwendung
US12529164B2 (en) 2007-09-14 2026-01-20 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
CN101855242B (zh) 2007-09-14 2014-07-30 阿迪马布有限责任公司 合理设计的合成抗体文库及其用途
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
WO2011137395A1 (en) 2010-04-30 2011-11-03 Rother Russell P Anti-c5a antibodies and methods for using the antibodies
CA2997745A1 (en) 2015-09-14 2017-03-23 Children's Hospital Medical Center Methods and compositions for treatment of gaucher disease via modulation of c5a receptor
WO2024220728A1 (en) * 2023-04-18 2024-10-24 Duke University Compositions and methods for raising mucosal and systemic immune responses against complement anaphylatoxins for inflammatory disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4237113B4 (de) 1992-11-03 2006-10-12 "Iba Gmbh" Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins
US5807824A (en) 1993-12-06 1998-09-15 Ciba-Geigy Corporation C5A receptor antagonists having substantially no agonist activity
US5696230A (en) 1994-08-31 1997-12-09 The Board Of Regents Of The University Of Nebraska High-affinity response-selective C-terminal analogs of C5a anaphylatoxin
EP0856055A1 (de) 1995-04-11 1998-08-05 Trustees Of Boston University Streptavidinmutanten
AUPO755097A0 (en) 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist

Also Published As

Publication number Publication date
US20060052294A1 (en) 2006-03-09
WO2003078457A1 (en) 2003-09-25
EP1492811A1 (de) 2005-01-05
JP4290564B2 (ja) 2009-07-08
JP2005536986A (ja) 2005-12-08
US8524862B2 (en) 2013-09-03
EP1492811B1 (de) 2011-09-21

Similar Documents

Publication Publication Date Title
NO20043891L (no) Anti-A-beta-antistoffer og deres anvendelse
ATE342917T1 (de) Antimikrobielle polypeptide aus pseudoplectania nigrella
ATE348883T1 (de) Zusammensetzungen und verfahren mit analogen von g-csf
RU2011147308A (ru) В ОСНОВНОМ НЕТОКСИЧНЫЙ МУТЕИН АЛЬФА-ТОКСИНА Clostridium perfringens И КОДИРУЮЩАЯ ЕГО МОЛЕКУЛА НУКЛЕИНОВОЙ КИСЛОТЫ
SG131109A1 (en) Muteins of tear lipocalin
NO20050998L (no) DNA som koder for et biologisk aktivt fragment av baktericid/premeabilitetsokende protein fremgangsmate for fremstilling av dette, samt farmasoytisk preparat inneholdende dette
AP2004003028A0 (en) Benzamide and heteroarylamide as P2X7 receptor antagonists
ATE302196T1 (de) N-adamantylalkyl benzamide derivativen als p2x7- rezeptor antagonisten
DK1761553T3 (da) MHC molecule-binding tumor-associated peptides
IL232501A0 (en) Stable analogs of medicinal peptides and polypeptides
BRPI0511421A (pt) composições cosmética e farmacêutica para tratar materiais contendo queratina, uso de composições cosméticas, molécula efetora que liga queratina, uso da mesma, e, processo
ATE525391T1 (de) Muteine des c5a anaphylatoxins, für solche muteine kodierende nukleinsäuremoleküle, sowie pharmazeutische verwendungen von muteinen des c5a anaphylatoxins
CY1114532T1 (el) (2r)-2-[(4-σουλφονυλ)αμινοφαινυλ]προπαναμιδια και φαρμακευτικες συνθεσεις περιεχοντας τα
BRPI0409736A (pt) anticorpos monoclonais, variantes de polipeptìdeo stop-1, molécula de ácido nucléico, vetor, célula hospedeira, composições, métodos relativos e artigos industrializados
CO5460266A1 (es) Novedosos analogos de la somatostatina
ATE308335T1 (de) Histidine-rich glycoprotein (hrgp) zur hemmung der angiogenese
WO2003002604A3 (en) G protein coupled receptors and dna sequences thereof
BRPI0407031A (pt) Composições e métodos para tratamento de câncer empregando igsf9 e liv-1
BR0213779A (pt) Molécula de ácido nucleico isolada, vetor, célula hospedeira, e, método para a preparação de um composto de quìmica fina
WO2005042717A3 (en) Primate prokineticin and prokineticin receptor polypeptides, related compositions and methods
BR0213574A (pt) Compostos básicos lineares apresentando atividade antagonista do nk-2 e formulações contendo os mesmos
DE60330116D1 (de) Aus fisch gewonnene peptide und nukleinsäuren der cathelicidin familie und deren verwendung
SG146640A1 (en) Isolated photoprotein mtclytin, and use thereof
BR0214056A (pt) Molécula de ácido nucleico isolada, vetor, célula hospedeira, e, método para a preparação de um composto de quìmica fina
Whitman et al. Nonpeptide αvβ3 antagonists. Part 9: Improved pharmacokinetic profile through the use of an aliphatic, des-amide backbone

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties